<div id="readability-page-1"><p>Clene (NASDAQ:CLNN - Get Free Report) posted its quarterly earnings results on Wednesday. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.25), FiscalAI reports. The business had revenue of $0.02 million for the quarter.</p><h2>Clene Trading Down 17.4%</h2><p>Shares of CLNN stock traded down $1.64 during trading hours on Thursday, reaching $7.77. 95,600 shares of the company's stock were exchanged, compared to its average volume of 88,419. Clene has a fifty-two week low of $2.28 and a fifty-two week high of $13.50. The stock's 50 day moving average is $8.10 and its 200-day moving average is $5.29. The company has a market cap of $78.24 million, a price-to-earnings ratio of -2.07 and a beta of 0.72. </p><h2>Institutional Inflows and Outflows</h2><p>An institutional investor recently bought a new position in Clene stock. Jane Street Group LLC acquired a new stake in  Clene Inc. (NASDAQ:CLNN - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor  acquired 12,095 shares of the company's stock, valued at approximately $47,000. Jane Street Group LLC owned approximately 0.15% of Clene at the end of the most recent reporting period. Institutional investors own  23.28% of the company's stock. </p><h2>Analyst Upgrades and Downgrades</h2><p>Several equities analysts have commented on the stock. Wall Street Zen lowered shares of Clene from a &#34;hold&#34; rating to a &#34;strong sell&#34; rating in a report on Saturday, August 16th. Canaccord Genuity Group cut their target price on shares of Clene from $83.00 to $48.00 and set a &#34;buy&#34; rating on the stock in a research report on Monday, August 18th. D. Boral Capital  reiterated a &#34;buy&#34; rating and set a $23.00 price objective on shares of Clene in a research report on Thursday, September 25th. Weiss Ratings  reaffirmed a &#34;sell (d-)&#34; rating on shares of Clene in a research report on Tuesday, October 14th. Finally, Benchmark dropped their price objective on Clene from $33.00 to $31.00 and set a &#34;buy&#34; rating on the stock in a research note on Wednesday, September 10th. Five research analysts have rated the stock with a Buy rating and one  has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of &#34;Moderate Buy&#34; and an average target price of $32.60.</p><p><b>View Our Latest Stock Report on Clene</b></p><h2>Clene Company Profile</h2> (Get Free Report)<p>Clene Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.</p><h2>Read More</h2><ul><li>Five stocks we like better than Clene</li><li>Election Stocks: How Elections Affect the Stock Market</li><li>AMD to $300 Looks Easy—Here’s Why $500 Could Be Next</li><li>How to Buy Cheap Stocks Step by Step</li><li>$5B+ in Buybacks: What DraftKings, AppLovin, and Altria Are Telling You </li><li>Insider Buying Explained: What Investors Need to Know</li><li>4 High-Yield Real Estate Stocks to Buy as Investors Get Defensive</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0xOTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0xOTg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Clene Right Now?</h2><p>Before you consider Clene, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Clene wasn't on the list.</p><p>While Clene currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

CLNN

<p>Clene (NASDAQ:CLNN) reported a quarterly earnings per share (EPS) of ($0.85), missing the consensus estimate by $0.25. The company's revenue for the quarter was $0.02 million. Following the earnings report, Clene's stock fell 17.4% to $7.77. Institutional investors own 23.28% of the stock, with recent activity from Jane Street Group LLC. Analysts have mixed ratings, with a Moderate Buy consensus and a target price of $32.60.</p>

Clene (NASDAQ:CLNN) Posts Quarterly Earnings Results, Misses Estimates By $0.25 EPS